Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
Abstract Targeted therapies for chronic myeloid leukaemia (CML) are effective, but rarely curative. Patients typically require treatment indefinitely, which gives ample time for drug resistance to evolve. Drug resistance issues are one of the main causes of death owing to CML, thus any means of prev...
Main Authors: | H. Jonathan G. Lindström, Ran Friedman |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-03-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-09048-5 |
Similar Items
-
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation
by: E Loveman, et al.
Published: (2012-05-01) -
Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia.
by: Haneen Banjar, et al.
Published: (2017-01-01) -
The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review
by: R. Garside, et al.
Published: (2002-01-01) -
Imatinib en leucemia mieloide crónica Imatinib in chronic myeloid leukemia
by: Valia Pavón Morán, et al.
Published: (2005-12-01) -
Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
by: Gian Paolo Bombeccari, et al.
Published: (2017-12-01)